XPOVIO® Expands Commercial Presence in APAC: Indonesia Approval Boosts Market Penetration

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company, has announced that the Indonesia National Agency of Drug and Food Control (BPOM) has approved a New Drug Application (NDA) for XPOVIO® (selinexor) for three indications. This approval further expands Antengene's commercial presence in the Asia-Pacific (APAC) region, following previous approvals in Thailand, Malaysia, and other markets.

XPOVIO® is the world's first approved orally-available, selective XPO1 inhibitor, offering a novel mechanism of action that sets it apart from existing treatments. This unique mechanism allows XPOVIO® to deliver synergistic effects in combination regimens, fast onset of action, and durable responses. With a growing demand for innovative medicines in the APAC region, XPOVIO®'s approval in Indonesia presents significant market opportunities and revenue streams for Antengene.

The approval of XPOVIO® in Indonesia, along with other APAC markets, is a testament to Antengene's successful market penetration strategy, driven by several key factors:

1. Novel Mechanism of Action: XPOVIO®'s unique mechanism of action sets it apart from existing treatments, offering a compelling value proposition for patients and healthcare providers.
2. Growing Demand for Innovative Medicines: The APAC region, with its steady economic growth and a population exceeding 600 million, has a growing demand for novel therapeutics. The accelerating aging population in ASEAN has increased the overall disease burden on patients and local communities, leading to a greater need for innovative medicines like XPOVIO®.
3. Public Health Insurance Coverage: XPOVIO® has been approved for health insurance coverage in five APAC markets, including the mainland of China, Taiwan market, Australia, Singapore, and South Korea. This inclusion in public insurance schemes reduces the financial burden on patients and increases accessibility to the treatment, further driving market penetration.
4. Expanding Indications: Antengene is actively exploring the development of multiple combination regimens of XPOVIO® for the treatment of various additional indications, such as myelofibrosis (MF) and endometrial cancer. This strategy allows XPOVIO® to reach a broader patient population and solidifies its position in the APAC market.
5. Strategic Partnerships: Antengene's collaboration with Karyopharm Therapeutics Inc. (Nasdaq:KPTI) has been instrumental in the development and commercialization of XPOVIO®. This partnership has enabled Antengene to leverage Karyopharm's expertise and resources to bring XPOVIO® to more APAC markets.

In conclusion, the approval of XPOVIO® in Indonesia, along with other APAC markets, is a testament to Antengene's successful market penetration strategy, driven by the drug's novel mechanism of action, growing demand for innovative medicines, public health insurance coverage, expanding indications, and strategic partnerships. As XPOVIO® gains approval in more APAC markets and is included in their national health insurance schemes, Antengene can expand its commercial presence and reach a larger patient population, driving commercial success and improving the level of healthcare in these regions.